Protembis GmbH, an Aachen, Germany-based medical technology startup, closed a $10m Series A financing.
– Abiomed Inc.,
– Seed Fonds III for the region of Aachen and Mönchengladbach GmbH & Co. KG,
– coparion GmbH & Co.
The company intends to use the funds to conduct further clinical studies in renowned heart centers in Europe and the U.S.A. and bring its product to market maturity.
Co-founded by Karl von Mangoldt and Conrad Rasmus, and also led by Oliver Schumacher, Chief Technology Officer, Protembis develops a catheter-based filter system to protect patients undergoing interventional heart procedures from stroke and other neurological injuries.
The “ProtEmbo Cerebral Protection System” – also called the “ProtEmbo” – aims to minimize the risk of stroke and other neurological injury in heart valve interventions.
Protembis has already demonstrated the initial safety and feasibility of the ProtEmbo in a first-in-human clinical study – the effectiveness of the technology was also shown. The company now plans to conduct further clinical studies in renowned heart centers in Europe and the U.S.A.